Compare · GILD vs INKT
GILD vs INKT
Side-by-side comparison of Gilead Sciences Inc. (GILD) and MiNK Therapeutics Inc. (INKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and INKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 3846.9x INKT ($50.7M).
- Over the past year, GILD is up 27.2% and INKT is down 27.8% - GILD leads by 54.9 points.
- GILD has been more active in the news (6 items in the past 4 weeks vs 4 for INKT).
- GILD has more recent analyst coverage (25 ratings vs 8 for INKT).
- Company
- Gilead Sciences Inc.
- MiNK Therapeutics Inc.
- Price
- $156.22-0.76%
- $10.82-6.03%
- Market cap
- $195.13B
- $50.7M
- 1M return
- +3.48%
- -13.62%
- 1Y return
- +27.19%
- -27.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 8
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
MiNK Therapeutics Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest INKT
- SEC Form 4 filed by MiNK Therapeutics Inc.
- SEC Form 144 filed by MiNK Therapeutics Inc.
- MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
- MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
- Director Wiinberg Ulf was granted 1,279 shares, increasing direct ownership by 6% to 23,929 units (SEC Form 4)
- Director Behner Peter was granted 1,485 shares, increasing direct ownership by 6% to 24,404 units (SEC Form 4)
- Director Holcomb John Bradley was granted 1,233 shares, increasing direct ownership by 36% to 4,691 units (SEC Form 4)
- Director Ryan Barbara was granted 1,622 shares, increasing direct ownership by 7% to 23,591 units (SEC Form 4)
- Director Corvese Brian was granted 1,633 shares, increasing direct ownership by 3% to 54,770 units (SEC Form 4)
- SEC Form S-8 filed by MiNK Therapeutics Inc.